This new distribution agreement represents the latest step towards Omni Health multi-year plan of making its next-generation anti-aging CBD products available for global distribution. Under the terms of the agreement, Omni Health will be developing and reformulating some of its existing products for distribution in more than 22 countries in Europe commencing on March 2018.

Andrey Soloviev, Omni Health Chief Executive Officer, stated: “We are excited to partner with MediCann which brings long standing relationships with key distributors in Europe.  With a population of more than 740 million people and a strong consumer demand for anti-aging and CBD products, European countries represent an attractive new growth opportunity,” He added: “This €3,700,000 deal is one of several now in works for further global distribution and licensing of a very strong portfolio of formulations Omni Health has developed over the past 4 decades. We are pleased that there is much here for us to build upon to develop new market and application opportunities.”

“We are extremely honored to work with Omni Health because of their decades of experience in bringing innovative healthcare products to market. We are looking forward to distribute Omni Health products throughout Europe.” said Carsten SIegemund, CEO of MediCann.

This latest development strategically positions Omni Health at the forefront of global CBD consumer goods market, and will further strengthen its P&L and financial positions.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies.